NYSE:NAVB Navidea Biopharmaceuticals (NAVB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Navidea Biopharmaceuticals Stock (NYSE:NAVB) Get NAVB alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume7,146 shsMarket Capitalization$10 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Navidea Biopharmaceuticals, Inc. is a biotechnology company focused on precision medicine, with an emphasis on radiopharmaceuticals and agents designed to target immune cells and lymphatic tissue. Its research is based primarily on the Manocept platform, which is intended to support diagnostic imaging and potential therapeutic applications in diseases involving the immune system. The company’s best-known product is Lymphoseek (technetium Tc 99m tilmanocept injection), a radiopharmaceutical used to help identify and map lymph nodes during procedures involving certain cancers, including breast cancer and melanoma. Lymphoseek has received regulatory approval in the United States and Europe for specified lymphatic mapping applications. Navidea has also pursued additional diagnostic and therapeutic uses of the Manocept platform, including investigational applications in inflammatory and immune-mediated diseases. Navidea was formerly known as Neoprobe and adopted its current name in 2012 as it shifted its focus toward the Manocept technology. The company has worked with commercial and development partners to support the distribution and further development of its products in the United States and international markets. Its pipeline beyond Lymphoseek remains focused on investigational programs, and product availability and development status may vary by geography.AI Generated. May Contain Errors. Read More Receive NAVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAVB Stock News HeadlinesNavidea Biopharmaceuticals, Inc. Files for BankruptcyOctober 8, 2025 | businesswire.comNavidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock SplitMay 21, 2025 | businesswire.comShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.September 24 at 1:00 AM | Digest Publishing (Ad)Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax AssetsMarch 31, 2025 | businesswire.comNavidea Biopharmaceuticals Inc. (NAVB) Latest Pre Market TradesDecember 23, 2024 | nasdaq.comNavidea Biopharmaceutical (OTC:NAVB) Stock Quotes, Forecast and News SummaryOctober 28, 2024 | benzinga.comNavidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024July 3, 2024 | businesswire.comNavidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024June 20, 2024 | businesswire.comSee More Headlines NAVB Stock Analysis - Frequently Asked Questions How were Navidea Biopharmaceuticals' earnings last quarter? Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) issued its earnings results on Wednesday, November, 10th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. The firm had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.60 million. How do I buy shares of Navidea Biopharmaceuticals? Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Navidea Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Navidea Biopharmaceuticals investors own include Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), CorMedix (CRMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), Advanced Micro Devices (AMD) and Catalyst Pharmaceuticals (CPRX). Company Calendar Last Earnings11/10/2021Today9/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:NAVB CIK810509 Webwww.navidea.com Phone614-793-7500Fax614-793-7522Employees10Year Founded1983Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$8.13 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares100,080,000Free Float56,367,000Market Cap$10 thousand OptionableNo Data Beta1.76 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:NAVB) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...Behind the Markets | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
